AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20457366 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric intraocular lens (IOL) implantation
Number of subjects: 37
Study 20457366 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative corneal spherical aberration
Number of subjects: 37
Study 20457366 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically induced corneal spherical aberration
Number of subjects: 37
Study 17493072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 40
Study 17493072 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 40
Study 15461066 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IIa PAD treatment
Number of subjects: 280
Study 15461066 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IIb PAD treatment
Number of subjects: 280
Study 15461066 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III PAD treatment
Number of subjects: 280
Study 15461066 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IV PAD treatment
Number of subjects: 280
Study 15461066 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment costs
Number of subjects: 280
Study 15461066 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 280
Study 11427189 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative assessment by appropriately trained nurses (ATN)
Number of subjects: 1874
Study 11427189 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative assessment by pre-registration house officers (PRHO)
Number of subjects: 1874
Study 11427189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of pre-operative assessment by ATNs
Number of subjects: 1874
Study 9530765 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational training (10 sessions, attended at least 70%)
Number of subjects: 131
Study 9530765 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychoeducational training)
Number of subjects: 131
Study 7979855 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 62
Study 7979855 — intervention group
Group type: COMPARATOR
Intervention: No Tamoxifen (Placebo)
Number of subjects: 62
Study 2606594 — intervention group
Group type: EXPERIMENTAL
Intervention: MaxEPA fish oil diet (6 g daily for 6 weeks)
Number of subjects: 14
Study 2606594 — intervention group
Group type: COMPARATOR
Intervention: Standard diet rich in saturated lipids (control group)
Number of subjects: 14
Study 782136 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (BDA) 200 mug
Number of subjects: 21
Study 782136 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (BDA) 400 mug
Number of subjects: 21
Study 782136 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (BDA) 800 mug
Number of subjects: 21
Study 782136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 27176943 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity on Prescription (PaP) with conventional treatment
Number of subjects: 88
Study 27176943 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone (Control)
Number of subjects: 88
Study 25782227 — intervention group
Group type: EXPERIMENTAL
Intervention: GreenLight HPS 180-W laser (GLL)
Number of subjects: 62
Study 25782227 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 62
Study 23212498 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected sleep period (12:30 AM to 5:30 AM)
Number of subjects: 103
Study 23212498 — intervention group
Group type: COMPARATOR
Intervention: Standard intern schedule (no protected sleep)
Number of subjects: 103
Study 23212498 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected sleep period
Number of subjects: 103
Study 20644583 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT) with effluent flow rates >25 ml/kg per hour
Number of subjects: 0
Study 20644583 — intervention group
Group type: COMPARATOR
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 0
Study 18540016 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-implants
Number of subjects: 30
Study 18540016 — intervention group
Group type: COMPARATOR
Intervention: Headgear
Number of subjects: 30
Study 16411387 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban (escalating intravenous doses, 6-hour infusions: 1.7 to 183 microg/kg/h)
Number of subjects: 60
Study 16411387 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban (bolus dose: 30 or 120 microg/kg with 6-hour infusion: 60 or 140 microg/kg/h)
Number of subjects: 60
Study 16411387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12559941 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis (TL)
Number of subjects: 850
Study 12559941 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 850
Study 11303326 — intervention group
Group type: EXPERIMENTAL
Intervention: CMA/B hCC chymase gene polymorphism assessment
Number of subjects: 587
Study 11303326 — intervention group
Group type: EXPERIMENTAL
Intervention: CMA/B hCC chymase gene polymorphism assessment in female group without retinopathy
Number of subjects: 587
Study 8839525 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beta-agonists
Number of subjects: 48
Study 8839525 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 48
Study 8839525 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic subjects
Number of subjects: 48
Study 1538048 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 131
Study 1538048 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 131
Study 6432291 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus triple treatment (sodium fluoride, calcium, and vitamin D)
Number of subjects: 31
Study 6432291 — intervention group
Group type: COMPARATOR
Intervention: Only prednisone
Number of subjects: 31
Study 6432291 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Prednisone plus triple treatment and Only prednisone)
Number of subjects: 31
Study 31693997 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sets of 3 × 30‐second maximal sprints (E&S) during the first 3 hours
Number of subjects: 12
Study 31693997 — intervention group
Group type: COMPARATOR
Intervention: Work‐matched cycling without sprints (E)
Number of subjects: 12
Study 29178404 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically diagnosed rickets at baseline
Number of subjects: 1778
Study 27064797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1262
Study 27064797 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 1262
Study 24890170 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano polymer‐free sirolimus‐eluting stent (SES)
Number of subjects: 291
Study 24890170 — intervention group
Group type: COMPARATOR
Intervention: Partner durable‐polymer sirolimus‐eluting stent (SES)
Number of subjects: 291
Study 22369557 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term low dose aspirin therapy (75 mg and 150 mg)
Number of subjects: 308
Study 22369557 — intervention group
Group type: COMPARATOR
Intervention: Control group (not taking aspirin)
Number of subjects: 308
Study 19797410 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-Rapid Maxillary Expansion (SRME)
Number of subjects: 35
Study 19797410 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion (RME)
Number of subjects: 35
Study 19797410 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 35
Study 17274715 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic device
Number of subjects: 17
Study 17274715 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic device
Number of subjects: 17
Study 17274715 — intervention group
Group type: COMPARATOR
Intervention: Both devices
Number of subjects: 17
Study 16129528 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5-week balance training programme (n=11)
Number of subjects: 30
Study 16129528 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5-week balance training programme (n=8, volleyball group)
Number of subjects: 30
Study 16129528 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=11, no training)
Number of subjects: 30
Study 11966498 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 75 mg
Number of subjects: 29
Study 11966498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 10445639 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Number of subjects: 175
Study 10445639 — intervention group
Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 175
Study 7789484 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, 500 mg q.d. oral therapy for 3 days
Number of subjects: 40
Study 7789484 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin, 250 mg b.i.d. oral therapy for 10 +/- 2 days
Number of subjects: 40
Study 7789484 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 40
Study 7789484 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 40
Study 7789484 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin and Clarithromycin
Number of subjects: 40
Study 2887328 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 25 mg
Number of subjects: 12
Study 2887328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine, 10 mg
Number of subjects: 12
Study 2887328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine, 20 mg
Number of subjects: 12
Study 2887328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29877199 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)-mobilized PBMNC transplantation combined with standard of care (SOC)
Number of subjects: 107
Study 29877199 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) only
Number of subjects: 107
Study 26477842 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (Avastin) 1.25 mg
Number of subjects: 441
Study 26477842 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis) 0.5 mg
Number of subjects: 441
Study 26477842 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 441
Study 24491074 — intervention group
Group type: EXPERIMENTAL
Intervention: RAP-PIR
Number of subjects: 0
Study 24491074 — intervention group
Group type: COMPARATOR
Intervention: RAP-placebo
Number of subjects: 0
Study 24491074 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only waiting-list control
Number of subjects: 0
Study 23848427 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS + TAU
Number of subjects: 146
Study 23848427 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 146
Study 20224475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (0.625 mg)
Number of subjects: 7
Study 18160813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse with 0.2% NaF solution
Number of subjects: 10
Study 18160813 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpicks
Number of subjects: 10
Study 18160813 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with toothpaste containing 0.32% fluoride
Number of subjects: 10
Study 18160813 — intervention group
Group type: EXPERIMENTAL
Intervention: Flossing combined with brushing
Number of subjects: 10
Study 18160813 — intervention group
Group type: EXPERIMENTAL
Intervention: Gels (0.2% or 0.32%) alone and in combination with brushing
Number of subjects: 10
Study 18160813 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdental brush with fluoride gel after toothbrushing
Number of subjects: 10
Study 20622758 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision
Number of subjects: 3
Study 15786539 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with rabeprazole (10 mg twice daily), clarithromycin (200 mg twice daily) and amoxicillin (750 mg twice daily)
Number of subjects: 165
Study 15786539 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofalcone (100 mg thrice daily) plus the triple therapy
Number of subjects: 165
Study 15786539 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaprezinc (150 mg twice daily) plus the triple therapy
Number of subjects: 165
Study 11389501 — intervention group
Group type: EXPERIMENTAL
Intervention: New antifungal agents (specific agents not mentioned)
Number of subjects: 0
Study 11389501 — intervention group
Group type: COMPARATOR
Intervention: Historical control comparisons
Number of subjects: 0
Study 9159561 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg rifampicin once daily for 5 days
Number of subjects: 8
Study 9159561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7862817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous benztropine (2 mg)
Number of subjects: 5
Study 7862817 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (1 mg)
Number of subjects: 5
Study 7862817 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 5
Study 3655310 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week intramuscular lymphoblastoid interferon treatment
Number of subjects: 40
Study 3655310 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week intramuscular lymphoblastoid interferon treatment
Number of subjects: 40
Study 3655310 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 40
Study 11903319 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 20
Study 11903319 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 20
Study 11903319 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 20
Study 31304593 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg rectal misoprostol at urinary catheter insertion plus 400 μg rectally after abdominal closure (preoperative group, n=100)
Number of subjects: 200
Study 31304593 — intervention group
Group type: COMPARATOR
Intervention: 800 μg of rectal misoprostol after abdominal closure (postoperative group, n=100)
Number of subjects: 200
Study 28914260 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (Hd‐MTX) therapy (3 g/m2)
Number of subjects: 360
Study 28914260 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-dose methotrexate (Id‐MTX) therapy (0.5 g/m2)
Number of subjects: 360
Study 26972745 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NAL)
Number of subjects: 165
Study 26972745 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NAL) and prolonged exposure (PE)
Number of subjects: 165
Study 26972745 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 165
Study 26972745 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo and PE
Number of subjects: 165
Study 24642289 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dopa (150 mg)
Number of subjects: 0
Study 24642289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21611728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamically mixed Impregum Penta H DuoSoft (DMM)
Number of subjects: 290
Study 21611728 — intervention group
Group type: COMPARATOR
Intervention: Statically mixed Impregum Soft tray material (SAM)
Number of subjects: 290
Study 20621900 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin, 40 mg/d subcutaneously for 28 +/- 4 days after receiving open-label enoxaparin for an initial 10 +/- 4 days.
Number of subjects: 5963
Study 20621900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5963
Study 17442265 — intervention group
Group type: COMPARATOR
Intervention: Exposure with response prevention (ERP) in therapist's office
Number of subjects: 28
Study 17442265 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure with response prevention (ERP) in natural environments (home, work, public places, car)
Number of subjects: 28
Study 16351767 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil-based intravenous lipid emulsion (ILE)
Number of subjects: 13
Study 16351767 — intervention group
Group type: COMPARATOR
Intervention: Soyabean oil-based intravenous lipid emulsion (ILE)
Number of subjects: 13
Study 11942872 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (Group E)
Number of subjects: 81
Study 11942872 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (Group P)
Number of subjects: 81
Study 9796928 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 units BtxA (Dysport) + electrical stimulation (A)
Number of subjects: 24
Study 9796928 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 units BtxA (B)
Number of subjects: 24
Study 9796928 — intervention group
Group type: COMPARATOR
Intervention: Placebo + electrical stimulation (C)
Number of subjects: 24
Study 9796928 — intervention group
Group type: COMPARATOR
Intervention: Placebo (D)
Number of subjects: 24
Study 7658778 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved STD case management in intervention communities
Number of subjects: 12537
Study 7658778 — intervention group
Group type: COMPARATOR
Intervention: Standard care in comparison communities
Number of subjects: 12537
Study 7658778 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of HIV incidence
Number of subjects: 12537
Study 2698567 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (3 X 50 mg daily for 4 weeks)
Number of subjects: 6
Study 2698567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 week prior to gallopamil)
Number of subjects: 6
Study 1093651 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (trimethoprim, 80 mg and sulfamethoxazole, 400 mg) - single dose
Number of subjects: 184
Study 1093651 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (trimethoprim, 80 mg and sulfamethoxazole, 400 mg) - two doses
Number of subjects: 184
Study 1093651 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-SDZ (sulfadiazine, 400 mg and trimethoprim, 80 mg) - single dose
Number of subjects: 184
Study 1093651 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-SDZ (sulfadiazine, 400 mg and trimethoprim, 80 mg) - two doses
Number of subjects: 184
Study 30239450 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week biweekly lower-limb elastic band training (knee and hip extension)
Number of subjects: 30
Study 30239450 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 29151102 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium, Vitamin D, and Genistein supplementation
Number of subjects: 102
Study 29151102 — intervention group
Group type: COMPARATOR
Intervention: Calcium and Vitamin D supplementation
Number of subjects: 102
Study 25272194 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum ARB dose
Number of subjects: 200
Study 25272194 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg/hydrochlorothiazide 12.5 mg combination
Number of subjects: 200
Study 23188089 — intervention group
Group type: EXPERIMENTAL
Intervention: RULER Approach integrated into fifth- and sixth-grade English language arts classrooms
Number of subjects: 62
Study 23188089 — intervention group
Group type: COMPARATOR
Intervention: Standard ELA curriculum only (comparison schools)
Number of subjects: 62
Study 21665552 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration applied to the segmentally related site during assessment of PPTs
Number of subjects: 16
Study 21665552 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercised leg (DOMS affected)
Number of subjects: 16
Study 21665552 — intervention group
Group type: COMPARATOR
Intervention: Control leg (contralateral leg)
Number of subjects: 16
Study 19471949 — intervention group
Group type: COMPARATOR
Intervention: IV siplizumab (0.012 mg/kg and 0.04 mg/kg) given every 2 weeks for 8 doses
Number of subjects: 544
Study 19471949 — intervention group
Group type: COMPARATOR
Intervention: SC siplizumab (5 mg for 12 weeks, 5 mg for 6 weeks, and 7 mg for 4 weeks)
Number of subjects: 544
Study 19471949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study 16505664 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential gas delivery (SGD) mask at 8 L/min
Number of subjects: 8
Study 16505664 — intervention group
Group type: COMPARATOR
Intervention: Nonrebreathing mask (NRM)
Number of subjects: 8
Study 16505664 — intervention group
Group type: COMPARATOR
Intervention: Venturi oxygen mask
Number of subjects: 8
Study 12867391 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% given every evening
Number of subjects: 34
Study 12867391 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% and dorzolamide 2% fixed combination (TDFC) given twice daily
Number of subjects: 34
Study 12867391 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% and dorzolamide 2% fixed combination (TDFC) at 10:00 PM
Number of subjects: 34
Study 12867391 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% at 10:00 PM
Number of subjects: 34
Study 12867391 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% and dorzolamide 2% fixed combination (TDFC)
Number of subjects: 34
Study 10550446 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH (1-34) 50 units weekly (L group)
Number of subjects: 220
Study 10550446 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH (1-34) 100 units weekly (M group)
Number of subjects: 220
Study 10550446 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH (1-34) 200 units weekly (H group)
Number of subjects: 220
Study 10550446 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 220
Study 10550446 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (L, M, H)
Number of subjects: 220
Study 9076650 — intervention group
Group type: EXPERIMENTAL
Intervention: Center for Addiction and Pregnancy (CAP) model of care
Number of subjects: 100
Study 9076650 — intervention group
Group type: COMPARATOR
Intervention: CAP participants
Number of subjects: 100
Study 1680123 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 65